SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs jumps higher on getting nod for setting up green field project in Ethiopia

12 Dec 2019 Evaluate

Kilitch Drugs (India) is currently trading at Rs. 120.75, up by 4.95 points or 4.27% from its previous closing of Rs. 115.80 on the BSE.

The scrip opened at Rs. 118.90 and has touched a high and low of Rs. 123.15 and Rs. 118.90 respectively. So far 3158 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 242.40 on 23-Jan-2019 and a 52 week low of Rs. 93.40 on 05-Aug-2019.

Last one week high and low of the scrip stood at Rs. 123.15 and Rs. 113.95 respectively. The current market cap of the company is Rs. 186.68 crore.

The promoters holding in the company stood at 68.90%, while Institutions and Non-Institutions held 0.26% and 30.84% respectively.

Kilitch Drugs (India) has received approval for setting up of new green field project in Ethiopia in East Africa. The company has also received approval for signing of relevant agreement with Government of Ethiopia. The Board of Directors of the company at their meeting held on December 12, 2019, approved the same.

Kilitch Drugs (India) is an India-based company engaged in pharmaceutical business. The Company’s services range from manufacturing to marketing a host of formulations in all dosage forms, such as solid, liquid and parenteral forms.

Kilitch Drugs(India) Share Price

135.10 4.55 (3.49%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×